ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,921 to 1,940 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Dronedarone 400mg Bid vs Placebo: First Hospitalization for Cardiovascular Reason675 of 2,301

859 of 2,327

-7.6 points

-10.3 to -4.9

4,628NCT00174785

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

Dronedarone 400mg Bid vs Placebo: Death From Any Cause116 of 2,301

139 of 2,327

-0.9 points

-2.3 to 0.4

4,628NCT00174785

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

Dronedarone 400mg Bid vs Placebo: Adjudicated Cardiovascular Death63 of 2,301

90 of 2,327

-1.1 points

-2.2 to -0.1

4,628NCT00174785

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

AZD7442 vs Placebo: Incidence of ADA to AZD7442 in Serum403 of 3,086

34 of 1,540

10.9 points

9.4 to 12.2

4,626NCT04625725

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

Dronedarone 400mg Bid vs Placebo: serious adverse events456 of 2,291

489 of 2,313

-1.2 points

-3.6 to 1.1

4,604NCT00174785

A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation

Pharmacist Arm vs Usual Care: Rate (%) of 30-day Post-discharge Hospitalization and ED Visits (Including Hospitals at Least Statewide)595 of 2,288

610 of 2,314

-0.4 points

-2.9 to 2.2

4,602NCT04071951

Pharmacist Intervention to Reduce Post-Hospitalization Utilization

Adolescent Records - Intervention Exposed vs Adolescent Records - Unexposed: Retention in HIV Care1,570 of 2,123

1,855 of 2,472

-1.1 points

-3.6 to 1.4

4,595NCT02928900

Patient Actor Training to Improve HIV Services for Adolescents in Kenya

Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants With an Ultrasound at 18-22 Weeks2,293 of 3,065

1,134 of 1,522

0.3 points

-2.3 to 3.0

4,587NCT03360539

Nurse-Family Partnership Impact Evaluation in South Carolina

Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants Who Received Adequate Prenatal Care2,572 of 3,065

1,283 of 1,522

-0.4 points

-2.6 to 1.9

4,587NCT03360539

Nurse-Family Partnership Impact Evaluation in South Carolina

Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants With a Dental Visit During Pregnancy625 of 3,065

275 of 1,522

2.3 points

-0.1 to 4.7

4,587NCT03360539

Nurse-Family Partnership Impact Evaluation in South Carolina

Pregnant Women vs Non-Pregnant Women: Positive Berlin Questionnaire Indicative of Sleep Disordered Breathing1,343 of 4,074

96 of 503

13.9 points

9.9 to 17.4

4,577NCT00462306

Incidence of Obstructive Sleep Apnea in Pregnancy

Cabotegravir vs TDF/FTC: deaths from any cause4 of 2,281

7 of 2,285

-0.1 points

-0.5 to 0.2

4,566NCT02720094

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Cabotegravir vs TDF/FTC: serious adverse events117 of 2,281

109 of 2,285

0.4 points

-0.9 to 1.6

4,566NCT02720094

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Cabotegravir vs TDF/FTC: Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events2,106 of 2,280

2,116 of 2,282

-0.4 points

-1.9 to 1.2

4,562NCT02720094

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Cabotegravir vs TDF/FTC: Number of Participants With Grade 3 or 4 Liver-related Adverse Events (AEs)73 of 2,280

96 of 2,282

-1.0 points

-2.1 to 0.1

4,562NCT02720094

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Cabotegravir vs TDF/FTC: Number of Participants With Documented Incident HIV Infections During Steps 1 and 213 of 2,280

39 of 2,281

-1.1 points

-1.8 to -0.5

4,561NCT02720094

Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men

Participants Treated With Oseltamivir vs Participants Not Treated With Oseltamivir: serious adverse events24 of 2,578

11 of 1,975

0.4 points

-0.2 to 0.9

4,553NCT00884117

Influenza Resistance Information Study

Denosumab / Denosumab vs Placebo / Denosumab: Number of Participants With Non-Vertebral Fractures172 of 2,343

219 of 2,207

-2.6 points

-4.2 to -1.0

4,550NCT00523341

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

Denosumab / Denosumab vs Placebo / Denosumab: Number of Participants With Antibodies to Denosumab0 of 2,343

1 of 2,206

-0.0 points

-0.3 to 0.1

4,549NCT00523341

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

Denosumab/ Denosumab 60 mg Q6M vs Placebo/ Denosumab 60 mg Q6M: serious adverse events1,014 of 2,343

945 of 2,206

0.4 points

-2.4 to 3.3

4,549NCT00523341

Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=97"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=97

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT00174785-8a9b5021",
        "title": "Dronedarone 400mg Bid vs Placebo: First Hospitalization for Cardiovascular Reason",
        "summary": "675 of 2301 against 859 of 2327; risk difference -7.6 points, 95% interval -10.3 to -4.9; NCT00174785, A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation",
        "record": "/library/comparisons/NCT00174785-8a9b5021",
        "nct_id": "NCT00174785",
        "kind": "outcome",
        "participants": 4628,
        "risk_difference": {
          "value": -0.0757941045792575,
          "lower": -0.10272508349976558,
          "upper": -0.04870187898795293
        },
        "group_1": "675 of 2,301",
        "group_2": "859 of 2,327",
        "difference": "-7.6 points",
        "interval": "-10.3 to -4.9",
        "trial_title": "A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation"
      },
      {
        "id": "NCT00174785-d622aee0",
        "title": "Dronedarone 400mg Bid vs Placebo: Death From Any Cause",
        "summary": "116 of 2301 against 139 of 2327; risk difference -0.9 points, 95% interval -2.3 to 0.4; NCT00174785, A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation",
        "record": "/library/comparisons/NCT00174785-d622aee0",
        "nct_id": "NCT00174785",
        "kind": "outcome",
        "participants": 4628,
        "risk_difference": {
          "value": -0.009320698554672609,
          "lower": -0.02255314169192054,
          "upper": 0.003868715407865075
        },
        "group_1": "116 of 2,301",
        "group_2": "139 of 2,327",
        "difference": "-0.9 points",
        "interval": "-2.3 to 0.4",
        "trial_title": "A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=98",
  "request_id": "Clg6rseKPMDB_Vc0"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?